# Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

Source: https://onco.cc/trials/nct06632951/  
OnCo record `nct06632951` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Livmoniplimab, Budigalimab, Docetaxel and Gemcitabine in bladder & urothelial cancer, run by AbbVie, active and no longer recruiting.

## Summary

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) is a phase 2 interventional study registered as NCT06632951 by AbbVie, with 150 participants enrolled, started 2025-01-20 and due to reach its primary completion in 2027-03. Interventions recorded: Livmoniplimab, Budigalimab, Docetaxel, Paclitaxel and Gemcitabine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06632951
- Phase: 2
- Setting: A Phase 2, Open-Label, Randomized Study of Livmoniplimab in Combination With Budigalimab Versus Chemotherapy in Subjects With Metastatic Urothelial Carcinoma
- Sponsor: AbbVie
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT06632951: https://clinicaltrials.gov/study/NCT06632951

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Budigalimab](https://onco.cc/drugs/budigalimab/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Livmoniplimab](https://onco.cc/drugs/livmoniplimab/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct06632951.json